Trial | NCT01913964  Report issue

Title

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    None
To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.
Study Started
Oct 31
1997
Primary Completion
Oct 31
1997
Study Completion
Oct 31
1997
Last Update
Aug 01
2013
Estimate

Drug Acetylcarnitine

Drug Placebo

(sugar pill)

Acetyl-L-carnitine Experimental

2 g daily for 12 months

placebo Placebo Comparator

Criteria 

Inclusion Criteria:

workers who were 18 years of age or older
Workers who were infected by HCV and had a quantifiable serum HCV RNA level (as determined by polimerase chain reaction, COBAS AmpliPrep/COBAS TaqMan - ROCHE)
Cirrhotic workers with a Child-Pugh score less than 7

Exclusion Criteria:

workers who had other liver diseases
cancer
severe jaundice
pulmonary and renal chronic diseases,
prostatic diseases
autoimmune diseases
diabetes mellitus
decompensated cirrhosis
pregnancy
cardiopathy
hemoglobinopathies
hemocromatosis
major depression
severe psychiatric pathological conditions
No Results Posted